Zorifertinib

佐利替尼

Report date: 2024/11/22 17:11:34
NME

Base Information

Drug NameZorifertinib
Drug Alias Name盐酸佐利替尼Epidermal growth factor receptor tyrosine kinase inhibitor - AstraZenecaEGFR antagonist - AstraZenecaZorifertinib - AstraZeneca泽瑞尼 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR L858R inhibitorsEGFR 19del inhibitors
TargetsEGFR L858REGFR 19del
Therapy Area/IndicationsBrain metastasesCarcinoma, Non-Small-Cell LungMeningeal Neoplasms
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/11/15
Country/TerritoryUnited StatesSingaporeTaiwan +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAlpha Biopharma (Jiangsu) Co LtdAlpha Biopharma LtdAstrazeneca Investment (China) Co Ltd
Inactive CompaniesAstrazeneca PlcLyzz Alpha Holding Ltd
Active IndicationsBrain metastasesCarcinoma, Non-Small-Cell LungMeningeal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A